Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Revestive (teduglutide)
pCPA File Number:
21174
Negotiation Status:
Concluded with an LOI
Indication(s):
Short Bowel Syndrome (SBS)
Sponsor/Manufacturer:
Shire Pharma Canada ULC
CADTH Project Number:
SR0606-000
pCPA Engagement Letter Issued:
2020-02-21
Negotiation Process Concluded:
2020-10-28